[HTML][HTML] High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma
MO Ali, S Al Hadidi - Transplantation and Cellular Therapy, 2022 - Elsevier
The use of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is the
standard of care in patients who are deemed transplantation eligible. Novel therapies …
standard of care in patients who are deemed transplantation eligible. Novel therapies …
Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?
M Martino, AG Recchia, G Console… - Expert Opinion on …, 2017 - Taylor & Francis
ABSTRACT Introduction: High-Dose Chemotherapy and Autologous Stem Cell
Transplantation (ASCT) has long been established as the standard of care for eligible …
Transplantation (ASCT) has long been established as the standard of care for eligible …
[HTML][HTML] Augmenting autologous stem cell transplantation to improve outcomes in myeloma
Consolidation with high-dose chemotherapy and autologous stem cell transplantation
(ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma …
(ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma …
Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma
N Sharma, E Benson, Q Zhao, J Nunnelee… - Leukemia & …, 2023 - Taylor & Francis
The standard preparative regimen for autologous stem cell transplant (ASCT) in multiple
myeloma (MM) is 200 mg/m2 of intravenous melphalan; however, a dose of 140 mg/m2 is …
myeloma (MM) is 200 mg/m2 of intravenous melphalan; however, a dose of 140 mg/m2 is …
Role of hematopoietic stem cell transplantation in multiple myeloma
IN Garcia - Clinical Lymphoma Myeloma and Leukemia, 2015 - Elsevier
High-dose therapy followed by autologous stem cell transplantation (ASCT) has been the
standard frontline consolidative therapy for patients with newly diagnosed multiple myeloma …
standard frontline consolidative therapy for patients with newly diagnosed multiple myeloma …
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents
F Gay, F Cavallo, A Palumbo - Drugs, 2015 - Springer
Outcome of patients with multiple myeloma (MM) has greatly improved with the use of
autologous stem cell transplantation (ASCT) and new agents, such as immunomodulatory …
autologous stem cell transplantation (ASCT) and new agents, such as immunomodulatory …
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in …
M Martino, A Olivieri, M Offidani, E Vigna… - Expert Opinion on …, 2013 - Taylor & Francis
Introduction: The role of high-dose chemotherapy (HDC) followed by autologous-progenitor
cell transplantation (auto-HPCT) in the treatment of multiple myeloma (MM) continues to …
cell transplantation (auto-HPCT) in the treatment of multiple myeloma (MM) continues to …
Is there still a role for stem cell transplantation in multiple myeloma?
R Mina, S Lonial - Cancer, 2019 - Wiley Online Library
High‐dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard
of care for transplant‐eligible patients with newly diagnosed multiple myeloma (MM). The …
of care for transplant‐eligible patients with newly diagnosed multiple myeloma (MM). The …
[HTML][HTML] Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma is Ready for Primetime
D Kazandjian, O Landgren - Clinical advances in hematology & …, 2019 - ncbi.nlm.nih.gov
The significant advances made in the treatment of multiple myeloma (MM) have allowed for
a paradigm shift away from the early use of high-dose melphalan with autologous stem cell …
a paradigm shift away from the early use of high-dose melphalan with autologous stem cell …
Stem-cell transplantation in multiple myeloma: how far have we come?
CY Soekojo, SK Kumar - Therapeutic advances in …, 2019 - journals.sagepub.com
High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) has historically
been an essential part of multiple myeloma (MM) management since early studies …
been an essential part of multiple myeloma (MM) management since early studies …